论文部分内容阅读
目的制备重组人白介素-2(rhIL-2)壳聚糖鼻腔黏附微球。并评价其用于过敏性鼻炎的可能性。方法采用沉淀方法制备载药微球,并对其外观形态、粒径、Zeta电位、载药量以及体外释放行为进行考察。结果以相对分子质量较大的壳聚糖制备的微球具有较大的粒径。体外释放实验表明,rhIL-2壳聚糖微球具有一定的缓释效果。黏膜纤毛迁移速率实验显示壳聚糖微球具有黏膜黏附性。家兔过敏性鼻炎实验表明,鼻腔给予该制剂可以缓解过敏性鼻炎症状,减少打喷嚏的发生率并且降低血浆中NO的含量。结论 rhIL-2壳聚糖微球比相同剂量rhIL-2溶液具有更好的效果。
Objective To prepare recombinant human interleukin-2 (rhIL-2) chitosan nasal adhesion microspheres. And evaluate its potential for allergic rhinitis. Methods The drug-loaded microspheres were prepared by precipitation method. The morphology, particle size, Zeta potential, drug loading and in vitro release behavior were investigated. Results The microspheres prepared with larger molecular weight chitosan had larger particle size. In vitro release experiments showed that, rhIL-2 chitosan microspheres have a sustained release effect. Mucous cilia migration rate experiments showed that the chitosan microspheres had mucoadhesion. Rabbit allergic rhinitis experiments show that nasal administration of the preparation can relieve the symptoms of allergic rhinitis, reduce the incidence of sneezing and reduce the content of NO in plasma. Conclusion rhIL-2 chitosan microspheres have better effect than the same dose rhIL-2 solution.